Showing 431-440 of 3380 results for "".
Red Light vs Blue Light Therapy
https://practicaldermatology.com/series/pdt-in-practice/red-light-vs-blue-light-therapy/26993/Dr. Hamza D. Bhatti, a board-certified dermatologist and dually accredited fellowship-trained Mohs micrographic surgeon and cosmetic dermatologic surgeon, discusses the differences between red light and blue light photodynamic therapy (PDT), the advantages of each, and some off-label uses of PDT.Improving Outcomes with Fillers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/improving-outcomes-with-fillers/18740/For the most optimal outcomes when injecting fillers, Dr. Galadari says there are three essential steps: choose the right patient, choose the right filler, and choose the right injection technique. He shares his favorite types of fillers for specific areas and discusses when and why he uses a cannulThe State of Dermatology Entrepreneurship 2015
https://practicaldermatology.com/topics/practice-management/the-state-of-dermatology-entrepreneurship-2015/18913/William Ju, MD, President of Advancing Innovation in Dermatology talks about entrepreneurship in dermatology. Where are new ideas, technologies, and therapies coming from, and how will they move ahead? Dr. Ju talks about the role of the pharmaceutical industry and finding resources.PsO Many Options: The Expanded Psoriasis Landscape
https://practicaldermatology.com/topics/psoriasis/pso-many-options-the-expanded-psoriasis-landscape/18749/By Jeffrey Weinberg, MD and Seemal R. Desai, MDWith many new therapies coming out in oral, topical, and biologic forms, there are fewer unmet needs in psoriasis management now than ever before. Dr. Weinberg navigates the therapeutic landscape.DermwireTV: FDA Clears Roflumilast, Guselkumab for Pediatric Populations, Plus More
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-clears-roflumilast-guselkumab-for-pediatric-populations-plus-more/39732/This episode highlights two new important pediatric approvals for treatments in both atopic dermatitis and psoriatic disease, also features a clip from a recent YoungMD Connect (YMDC) mentorship session with Dr. Tina Bhutani covering both career paths in both academia and industry.DermwireTV: Deucravacitinib Maintains Efficacy in PsO at 3 Years
https://practicaldermatology.com/programs/practical-dermatology/dermwiretv-deucravacitinib-maintains-efficacy-in-pso-at-3-years/37249/In this episode of DermwireTV, deucravacitinib maintains efficacy for plaque psoriasis through 3 years in a new analysis; GLP-1 medications may be fueling a rise in aesthetic procedures, according to new research; and Drs. Tina Bhutani and Lisa Swanson weigh in on transitioning from academia to privHarnessing Psychology to Make Your Practice and Outside Life Better
https://practicaldermatology.com/topics/editorial/harnessing-psychology-make-your-practice-and-outside-life-better/26952/Harnessing Psychology to Make Your Practice and Outside Life BetterOf Pandemics and Postponements
https://practicaldermatology.com/topics/practice-management/of-pandemics-and-postponements/23342/Hyperpigmentation Treatment Pearls and More
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/hyperpigmentation-treatment-pearls-and-more/20161/Corey Hartman, MD shares his approach to treating periorbital hyperpigmentation in darker skin types, including using fillers to replace volume, give lift, and replace loss of bony structures and fat pads. Dr. Hartman also discusses the benefits of Cynosure’s PicoSure device to correct hyperpigmentaIdentifying SCC Risk
https://practicaldermatology.com/topics/skin-cancer-photoprotection/identifying-scc-risk/20144/Sherrif Ibrahim, MD discusses the challenges of managing squamous cell carcinoma (SCC). Great steps have been made in clinical, pathological staging systems, but Dr. Ibrahim says it’s still difficult to determine what to do with borderline cases. He talks about the need to determine frequency and in